VRON-0200 is under clinical development by Virion Therapeutics and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VRON-0200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VRON-0200 overview
Vaccine is under development for the treatment of hepatitis B. The vaccine candidate comprises of chimpanzee adenovirus serotype 6 and 7 vaccine vector. It is developed based on Chivax platform. It is administered via intramuscular route.
Virion Therapeutics overview
Virion Therapeutics, LLC, is a science driven company developing innovative immune-based treatments for virally-associated cancers and chronic viral infections. Our vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potent and sustained T cell-mediated immune responses against transformed or infected cells, thereby allowing us to target common diseases with unmet medical needs. Each component comprising our chimeric vaccine candidates has completed pre-clinical testing that allow for their translation into clinical trials for a number of different indications. Guided by our scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections.
For a complete picture of VRON-0200’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
